News
Home
/
News
/
News
/
DIAlogue | 访谈2019DIA中国第五届药物研发创新大会组委会主席王在琪博士
DIAlogue | 访谈2019DIA中国第五届药物研发创新大会组委会主席王在琪博士
2018-08-13 10:34
Previous
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
下一篇
写意人物丨王在琪：研发具有全球影响力的个体化治疗药物
Previous
:
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Next
:
写意人物丨王在琪：研发具有全球影响力的个体化治疗药物
Copyright © 2019 InxMed
冀
ICP备10238728号
Powered by 300.cn
EN
|
中文
